Previous 10 | Next 10 |
– Approval based on CheckMate -9ER trial, in which CABOMETYX in combination with OPDIVO doubled progression-free survival and objective response rate while significantly improving overall survival versus sunitinib – Exelixis, Inc. (Nasdaq: EXEL) today a...
Exelixis, Inc. (Nasdaq: EXEL) today announced that COSMIC-313, the phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX ® ), nivolumab (OPDIVO ® ) and ipilimumab (YERVOY ® ) versus the combination of nivolumab and ipilimumab in patie...
Exelixis is rapidly developing cabozantinib in many indications. Patent expiry may become a problem in about 5 years. By then, cabo may become a multibillion dollar blockbuster. For further details see: Exelixis: A Look At Its Potential
Exelixis (EXEL) announced a collaboration with Pfizer (PFE) and Merck KGaA (MKGAF) in an ongoing phase 1b dose-escalation study, STELLAR-001 for XL092, the company’s oral tyrosine kinase inhibitor targeting cancer growth and spread.Under the agreement, three new cohorts will ...
– New expansion cohorts to be added to ongoing STELLAR-001 trial following dose-escalation phase – Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for the on...
Exelixis, Inc. (EXEL) Oppenheimer 31st Annual Healthcare Conference March 16, 2021 11:20 AM ET Company Participants Michael Morrissey - CEO Conference Call Participants Jay Olson - Oppenheimer & Co. Presentation Jay Olson Hello everyone. And welcome to Oppenheimer’s 31st Annual Hea...
Exelixis, Inc. (EXEL) 2021 Barclays Global Healthcare Conference March 09, 2021 11:30 AM ET Company Participants Mike Morrissey - President, CEO Conference Call Participants Peter Lawson - Barclays Presentation Peter Lawson Great. Good morning everybody. Welcome to Barclays Healthcare Confere...
Exelixis ([[EXEL]] -0.7%) and WuXi Biologics tie up in an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline.Under the terms of the agreement, Exelixis will make a modest upfront payment to WuXi Bio in exchange for an exclusive licen...
– Exelixis has exclusive license to panel of monoclonal antibodies against an undisclosed oncology target for biologics applications, leveraging WuXi Biologics integrated technology platforms – – In addition to a modest upfront payment, WuXi Biologic...
Exelixis, Inc. (EXEL) Cowen 41st Annual Health Care Conference March 01, 2021 2:40 PM ET Company Participants Mike Morrissey – Chief Executive Officer Conference Call Participants Yaron Werber – Cowen Presentation Yaron Werber Good afternoon everybody and thank you once again fo...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...